| Citation: |
MA Xiao, LIU Wanhong. Classification and Gene Features of Unverified HAdV in China, 2012-2019[J]. Cancer Research on Prevention and Treatment, 2021, 48(6): 581-585. DOI: 10.3971/j.issn.1000-8578.2021.20.1416
|
To analyze the type and gene features of 11 unverified HAdVs in China.
We downloaded HAdV genome sequences of 67 strains with clear genotypes and the HAdV reference genome sequences of 7 strains from GenBank database, analyzed them together with eleven unverified HAdV gene sequences and classified the species of each sequence based on the genetic structure, sequence similarity and phylogenetic analysis.
Phylogenetic analysis results predicted the classification of six sequences: two of them belonged to HAdV-B and two belonged to HAdV-D (the gene homology were 97.8% and 92.8% in comparison with reference gene respectively), the rest of two sequences were not conclusive. Multiple sequence alignment was used to predict the species of five HAdVs. All of them belonged to species HAdV-B, the sequence similarity compared with reference gene was 97.9%.
Genotyping of the unverified HAdV genome from a genetic point of view predicts that seven strains might belong to species HAdV-B, two strains might belong to species HAdV-D and two strains could not be classified. The seven HAdV-B strains might be suitable for the treatment of osteosarcoma as oncolytic adenovirus.
Competing interests: The authors declare that they have no competing interests.
| [1] |
Mennechet FJD, Paris O, Ouoba AR, et al. A review of 65 years of human adenovirus seroprevalence[J]. Expert Rev Vaccines, 2019, 18(6): 597-613. doi: 10.1080/14760584.2019.1588113
|
| [2] |
Lynch 3rd JP, Kajon AE. Adenovirus: Epidemiology, Global Spread of Novel Serotypes, and Advances in Treatment and Prevention[J]. Semin Respir Crit Care Med, 2016, 37(4): 586-602. doi: 10.1055/s-0036-1584923
|
| [3] |
Chartier C, Degryse E, Gantzer M, et al. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli[J]. J Virol, 1996, 70(7): 4805-4810. doi: 10.1128/jvi.70.7.4805-4810.1996
|
| [4] |
Xing L, Tikoo SK. Promoter activity of left inverted terminal repeat and downstream sequences of porcine adenovirus type 3[J]. Virus Res, 2005, 109(1): 51-58. doi: 10.1016/j.virusres.2004.10.006
|
| [5] |
Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering[J]. Mol Ther, 2007, 15(4): 651-659. doi: 10.1038/sj.mt.6300108
|
| [6] |
Twumasi-Boateng K, Pettigrew JL, Kwok YYE, et al. Oncolytic viruses as engineering platforms for combination immunotherapy[J]. Nat Rev Cancer, 2018, 18(7): 419-432. doi: 10.1038/s41568-018-0009-4
|
| [7] |
Vogels R, Zuijdeest D, van Rijnsoever R, et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity[J]. J Virol, 2003, 77(15): 8263-8271. doi: 10.1128/JVI.77.15.8263-8271.2003
|
| [8] |
Bishop MW, Janeway KA, Gorlick R. Future directions in the treatment of osteosarcoma[J]. Curr Opin Pediatr, 2016, 28(1): 26-33. doi: 10.1097/MOP.0000000000000298
|
| [9] |
Baker AT, Aguirre-Hernández C, Halldén G, et al. Designer Oncolytic Adenovirus: Coming of Age[J]. Cancers (Basel), 2018, 10(6): 201. doi: 10.3390/cancers10060201
|
| [10] |
Burland TG. DNASTAR's Lasergene sequence analysis software[J]. Methods Mol Biol, 2000, 132: 71-91.
|
| [11] |
Kumar S, Stecher G, Tamura K. MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger Datasets[J]. Mol Biol Evol, 2016, 33(7): 1870-1874. doi: 10.1093/molbev/msw054
|
| [12] |
Scott MK, Chommanard C, Lu X, et al. Human Adenovirus Associated with Severe Respiratory Infection, Oregon, USA, 2013-2014[J]. Emerg Infect Dis, 2016, 22(6): 1044-1051. doi: 10.3201/eid2206.151898
|
| [13] |
Arnberg N. Adenovirus receptors: implications for targeting of viral vectors[J]. Trends Pharmacol Sci, 2012, 33(8): 442-448. doi: 10.1016/j.tips.2012.04.005
|
| [14] |
de Graaf JF, de Vor L, Fouchier RAM, et al. Armed oncolytic viruses: A kick-start for anti-tumor immunity[J]. Cytokine Growth Factor Rev, 2018, 41: 28-39. doi: 10.1016/j.cytogfr.2018.03.006
|
| [15] |
Nguyen TV, Crosby CM, Heller GJ, et al. Oncolytic adenovirus Ad657 for systemic virotherapy against prostate cancer[J]. Oncolytic Virother, 2018, 7: 43-51. doi: 10.2147/OV.S155946
|
Figures(1) / Tables(6)
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: